Market Place
Sourcing Support
Accutar Receives FDA Fast Track Designation For AC699 In ER+/HER2- Breast Cancer
14 Aug 2024 //
BUSINESSWIRE
Accurar`s AC699 Monotherapy Phase 1 Data In ER+/HER2- Breast Cancer
01 Jun 2024 //
BUSINESSWIRE
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
28 Nov 2023 //
PR NEWSWIRE
Accutar Announces First Patient Dosed with AC0676 in Phase 1 Study
20 Jun 2023 //
BUSINESSWIRE
Accutar Announces First Patient Dosed in China with AC0176 in Phase 1 Study
23 Feb 2023 //
BUSINESSWIRE
Accutar Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676
03 Feb 2023 //
BUSINESSWIRE
Accutar Announces First Patient Dosed in China with AC0682 in PhI Study
11 Oct 2022 //
BUSINESSWIRE
Accutar Receives NMPA Clearance of IND Application for AC0176
19 Aug 2022 //
BUSINESSWIRE
FDA Grants FTD to Accutar`s AC0176 for mCRPC
01 Jun 2022 //
BIOSPACE
Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682
01 Apr 2022 //
BUSINESSWIRE
Accutar Bio Announces First Patient Dosed with AC0176 in Phase 1 Study in mCRPC
30 Mar 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.